Malady Kyle 4

What Happened Kyle Malady, EVP and Group CEO — VZ Business, was granted 132.86 phantom shares (derivative award) on 2026-06-17 at an imputed value of $13.08 per share, totaling roughly $1,738. The Form 4 classifies this as an award/grant (code A) and the units are economic equivalents of Verizon common stock rather than actual shares.

Key Details

• Transaction date: 2026-06-17; filing date (Form 4): 2026-06-18 (appears to be filed timely).
• Units granted: 132.86 phantom shares at $13.08 each; total value ≈ $1,738.
• Shares owned after transaction: not specified in the provided filing.
• Footnotes: F1 — phantom shares are cash‑settled and payable under the deferred compensation plan; F2 — includes phantom stock acquired via dividend reinvestment.
• Transaction type: Award/Grant of derivative units (not an open‑market buy or sale).

Context Phantom stock is a deferred‑compensation vehicle that mirrors the economic value of common shares but is settled in cash based on plan rules; it does not transfer voting rights or actual shares. Such awards are routine executive compensation and do not by themselves indicate a buy/sell signal in the market.